Amneal Pharmaceuticals Inc

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

AMRX$21.38+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)

	Three Months Ended March 31,
	2025	2024
Net revenue	$695,420	$659,191
Cost of goods sold	439,529	421,131
Gross profit	255,891	238,060
Selling, general and administrative	118,288	112,595
Research and development	40,040	39,298
Intellectual property legal development expenses	1,767	984
Restructuring and other charges	571	1,470
Charges related to legal matters, net	—	94,359
Other operating (income) expense	(5,122)	100
Operating income (loss)	100,347	(10,746)
Other (expense) income:
Interest expense, net	(56,939)	(65,703)
Foreign exchange gain (loss), net	4,247	(1,197)
Increase in tax receivable agreement liability	(10,687)	(1,948)
Other income, net	518	4,072
Total other expense, net	(62,861)	(64,776)
Income (loss) before income taxes	37,486	(75,522)
Provision for income taxes	12,868	6,156
Net income (loss)	24,618	(81,678)
Less: Net income attributable to non-controlling interests	(12,423)	(9,965)
Net income (loss) attributable to Amneal Pharmaceuticals, Inc.	$12,195	$(91,643)
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic	$0.04	$(0.30)
Diluted	$0.04	$(0.30)
Weighted-average common shares outstanding:
Basic	311,054	307,279
Diluted	323,961	307,279

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.